Il y a eu 50 transactions d'initiés récentes enregistrées pour Stoke Therapeutics, Inc. (STOK), dont 13 achats et 36 ventes. Le total des achats d'initiés s'élève à $1.95M et le total des ventes d'initiés à $33.17M.
Les initiés notables ayant une activité récente comprennent Ticho Barry, Allan Jonathan, Hoitt Jason. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — STOK
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-04-01 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
1,838 |
$32.66 |
$60.03K |
38,864 |
| 2026-03-20 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
601 |
$34.41 |
$20.68K |
19,543 |
| 2026-03-19 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
1,461 |
$29.99 |
$43.82K |
40,702 |
| 2026-03-18 |
Hoitt Jason |
Chief Patient Officer |
Vente Informative |
30 |
$32.85 |
$985.50 |
10,276 |
| 2026-03-18 |
Leggett Thomas |
Chief Financial Officer |
Vente Informative |
37 |
$32.85 |
$1.22K |
10,172 |
| 2026-03-18 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
103 |
$32.85 |
$3.38K |
40,798 |
| 2026-03-18 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
72 |
$32.85 |
$2.37K |
28,836 |
| 2026-03-17 |
Hoitt Jason |
Chief Patient Officer |
Vente Informative |
748 |
$33.38 |
$24.96K |
12,207 |
| 2026-03-17 |
Leggett Thomas |
Chief Financial Officer |
Vente Informative |
922 |
$33.38 |
$30.77K |
12,554 |
| 2026-03-17 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
2,587 |
$33.38 |
$86.34K |
47,484 |
| 2026-03-17 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
1,791 |
$33.38 |
$59.78K |
33,464 |
| 2026-03-15 |
Kaye Edward M. Md |
Director |
Exercice d'Options (Vente) |
35,500 |
- |
- |
35,500 |
| 2026-03-15 |
Hoitt Jason |
Chief Patient Officer |
Exercice d'Options |
10,000 |
- |
- |
13,988 |
| 2026-03-15 |
Leggett Thomas |
Chief Financial Officer |
Exercice d'Options |
14,750 |
- |
- |
14,750 |
| 2026-03-15 |
Ticho Barry |
Chief Medical Officer |
Exercice d'Options (Vente) |
13,100 |
- |
- |
13,100 |
| 2026-03-15 |
Allan Jonathan |
General Counsel & Corp Sec |
Exercice d'Options (Vente) |
7,475 |
- |
- |
7,475 |
| 2026-03-13 |
Levin Arthur A |
Director |
Vente Informative |
605 |
$36.80 |
$22.26K |
4,237 |
| 2026-03-10 |
Tzianabos Arthur |
Interim Executive Chair |
Vente Informative |
4,355 |
$40.00 |
$174.21K |
31,339 |
| 2026-03-10 |
Krainer Adrian R. |
Director |
Vente Informative |
33,243 |
$39.74 |
$1.32M |
283,302 |
| 2026-03-02 |
Krainer Adrian R. |
Director |
Vente Informative |
7,229 |
$39.66 |
$286.72K |
316,545 |
| 2026-02-17 |
Smith Ian F |
Chief Executive Officer |
Attribution de RSU |
129,000 |
- |
- |
129,000 |
| 2026-02-17 |
Hoitt Jason |
Chief Patient Officer |
Attribution de RSU |
48,000 |
- |
- |
48,000 |
| 2026-02-17 |
Leggett Thomas |
Chief Financial Officer |
Attribution de RSU |
40,000 |
- |
- |
40,000 |
| 2026-02-17 |
Ticho Barry |
Chief Medical Officer |
Attribution de RSU |
40,000 |
- |
- |
40,000 |
| 2026-02-17 |
Allan Jonathan |
General Counsel & Corp Sec |
Attribution de RSU |
35,000 |
- |
- |
35,000 |
| 2025-12-31 |
Levin Arthur A |
Director |
Exercice d'Options (Vente) |
1,211 |
- |
- |
- |
| 2025-12-08 |
Kaye Edward M. Md |
Director |
Vente Informative |
1,331 |
$33.10 |
$44.06K |
49,124 |
| 2025-12-08 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
2,678 |
$32.61 |
$87.34K |
11,831 |
| 2025-12-05 |
Kaye Edward M. Md |
Director |
Vente Informative |
500 |
$31.85 |
$15.92K |
62,554 |
| 2025-12-05 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
1,989 |
$31.35 |
$62.35K |
19,798 |
| 2025-12-05 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
2,344 |
$31.76 |
$74.44K |
15,809 |
| 2025-12-04 |
Kaye Edward M. Md |
Director |
Vente Informative |
1,231 |
$31.32 |
$38.55K |
71,102 |
| 2025-12-04 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
323 |
$31.32 |
$10.12K |
23,460 |
| 2025-12-04 |
Allan Jonathan |
General Counsel & Corp Sec |
Vente Informative |
194 |
$31.32 |
$6.08K |
24,594 |
| 2025-12-03 |
Kaye Edward M. Md |
Director |
Vente Informative |
651 |
$30.85 |
$20.08K |
51,305 |
| 2025-12-03 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
1,225 |
$30.85 |
$37.79K |
15,156 |
| 2025-12-03 |
Kaye Edward M. Md |
Director |
Exercice d'Options (Vente) |
26,250 |
- |
- |
- |
| 2025-12-03 |
Ticho Barry |
Chief Medical Officer |
Exercice d'Options (Vente) |
10,000 |
- |
- |
- |
| 2025-12-03 |
Allan Jonathan |
General Counsel & Corp Sec |
Exercice d'Options (Vente) |
6,000 |
- |
- |
- |
| 2025-12-02 |
Kaye Edward M. Md |
Director |
Vente Informative |
405 |
$30.14 |
$12.21K |
52,375 |
| 2025-12-02 |
Ticho Barry |
Chief Medical Officer |
Vente Informative |
762 |
$30.14 |
$22.97K |
17,170 |
| 2025-12-01 |
Ticho Barry |
Chief Medical Officer |
Exercice d'Options (Vente) |
11,981 |
- |
- |
- |
| 2025-06-18 |
Hoitt Jason |
Chief Patient Officer |
Inconnu |
40,000 |
- |
- |
- |
| 2025-06-04 |
Skorpios Trust |
10 Percent Owner |
Vente Informative |
3,000,000 |
$10.20 |
$30.6M |
3,906,181 |
| 2025-06-03 |
Levin Arthur A |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
| 2025-06-03 |
Harrison Seth Loring |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
| 2025-06-03 |
Menzel Garry E |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
| 2025-06-03 |
Smith Julie |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
| 2025-06-03 |
Burstein Jennifer |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
| 2025-06-03 |
Krainer Adrian R. |
Director |
Attribution de RSU |
29,747 |
$10.90 |
$324.24K |
29,747 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
